How can 'Hy's law' help the clinician?

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 4, 2006, Pages 235-239

  Senior, John R ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BENOXAPROFEN; BILIRUBIN; BROMFENAC; CELECOXIB; DURAC; IBUPROFEN; MELOXICAM; NAPROXEN; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; THROMBIN INHIBITOR; TIENILIC ACID; TROGLITAZONE; VALDECOXIB; XIMELAGATRAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; DRUG APPROVAL; DRUG FATALITY; DRUG WITHDRAWAL; FALSE POSITIVE RESULT; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LIVER CELL DAMAGE; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; META ANALYSIS; NONHUMAN; NOTE; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALANINE TRANSAMINASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; AZETIDINES; BENZOPHENONES; BENZYLAMINES; BILIRUBIN; BIOLOGICAL MARKERS; BROMOBENZENES; CHROMANS; DRUG APPROVAL; HEPATITIS, TOXIC; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; THIAZOLIDINEDIONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33646024905     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1210     Document Type: Note

References (25)

1. Lewis JH. 'Hy's Law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: Putting risk-benefit into perspective. PD Safe 2005; in press.
2. FDA Advisory Committee. Ximelagatran for prevention of thromboembolic events in chronic atrial fibrillation. [Verbatim transcript of meeting 10 September 2004 ] (Accessed 27 September 2005 at http://www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4069T1.htm)
3. Davidson CS, Leevy CM, Chamberlayne EC (eds). Chapter 8, Guidelines for evaluation of potential hepatotoxicity of drugs in clinical trials. In Guidelines for detection of hepatotoxicity due to drugs and chemicals. [Fogarty Conference] NIH, USA. Publication No. 79-313, 1978; 106-118.
4. Reuben A. Hy's Law. [Landmarks in Hepatology]. Hepatology 2004; 39: 574-578.
5. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481-489.
6. Andrade RL, Lucena MI, Fernández MC, et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521.
7. Zimmerman HJ. Chapter 16: Drug-induced liver disease. In Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. (1st edn), Appleton-Century-Crofts: New York, 1978; 353.
8. Zimmerman HJ. Chapter 16, Drug-induced liver disease. In Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. (2nd edn), Lippincott Williams & Wilkins: Philadelphia, 1999; 433.
9. Agress CM, Jacobs HI, Glassner HF, et al. Serum transaminase levels in experimental myocardial infarction. Circulation 1955; 11: 711-713.
10. Karmen A. A note on the spectrophotometric assay of glutamic-oxalacetic transaminase in human blood serum. J Clin Invest 1955; 34: 131-133. (Appendix to Karmen A, Wrobleski F, LaDue J. Transaminase activity in human blood. J Clin Invest 1955; 34: 126-131).
11. FDA Working Group. Clinical white paper, November 2000, conference on Drug-Induced Liver Injury: A National and Global Problem, 12-13 February 2001, Chantilly VA. [Accessed 27 September 2005] at (http://www.fda.gov/cder/livertox/clinical.pdf))
12. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs. - I: A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330.
13. Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs.-II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-1336.
14. Lee WM, Senior JR. Recognizing drug-induced liver injury; current problems, possible solutions. Toxicol Pathol 2005; 33: 155-164.
15. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isonizid preventative therapy: A 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281: 1014-1018.
16. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Safe 2005; 28: 351-370.
17. Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: Lessons learned from the bromfenac experience. PD Safe 2005; in press.
18. Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: A systematic review of randomized controlled trial in arthritis patients. Clin Gastroenterol Hepatol 2005; 3: 489-498.
19. Hyde JE, Widmark RM. Bromfenac safety summary, 23 April 2005. [Accessed 27 September 2005] at (http://www.fda.gov/cder/foi/nda/97/020535ap_Duract_medrP1.pdf)
20. Moses PL, Schroeder B, Alkhatib O, Ferrentino N, Suppan T, Lidofsky SD. Severe toxicity associated with bromfenac sodium. Am J Gastroenterol 1999; 94: 1393-1396.
21. Hunter EB, Johnston PE, Tanner G, Pinson CW, Awad JA. Bromfenac (Duract)-associated hepatic failure requiring liver transplantation. Am J Gastroenterol 1999; 94: 2299-2301.
22. Rabkin JM, Smith MJ, Orloff SL, Corless CL, Stenzel P, Olyaei AJ. Fatal fulminant hepatitis associated with bromfenac use. Ann Pharmacother 1999; 33: 945-947.
23. Fontana RJ, McCashland TM, Benner KG, et al. Acute liver failure associated with prolonged use of bromfenac leading. to liver transplantation. Liver Transpl Surg 1999; 5: 480-484.
24. Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001; 286: 831-833.
25. Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: A case study. Am J Med 2003; 114: 299-306.